Trial Profile
An Open-Label, Multicenter, Proof of Concept, Phase 2 Study Evaluating the Results of Tc99m-Maraciclatide Scintigraphy in Subjects With Diabetes Mellitus (DM) and Heart Failure With Preserved Left Ventricular Ejection Fraction (HFPEF)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 26 May 2014
Price :
$35
*
At a glance
- Drugs Maraciclatide (Primary)
- Indications Cardiovascular disorders
- Focus Diagnostic use
- Sponsors GE Healthcare
- 26 May 2014 New trial record